Novartis announces planned acquisition of Endocyte for $2.1 billion
Novartis announced that it has entered into an agreement and plan of merger with Endocyte, a US-based biopharmaceutical company focused on developing targeted therapeutics for cancer treatment. Novartis would acquire all outstanding shares of Endocyte common stock for $24 per share. October 18, 2018